Ignite Creation Date:
2025-12-25 @ 4:55 AM
Ignite Modification Date:
2026-04-14 @ 1:43 PM
Study NCT ID:
NCT05312918
Status:
UNKNOWN
Last Update Posted:
2022-04-06
First Post:
2021-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)
Sponsor:
ANRS, Emerging Infectious Diseases
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-10
Completion Date Type:
ESTIMATED
First Submit Date:
2021-09-22
First Submit QC Date:
None
Study First Post Date:
2022-04-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-03-28
Last Update Post Date:
2022-04-06
Last Update Post Date Type:
ACTUAL